Stada Arzneimittel

This sponsor has funded 8 studies across 13 countries.

PAS funded by this sponsor.
EU PAS ID Status Title Protocol uploaded Results uploaded
7619 Finalised Risk of Venous Thromboembolism and All-Cause Mortality in Cancer Patients Treated with Epoetins either with or without Transfusions versus Cancer... No Yes
10254 Finalised Thromboembolic Risk in Patients with Chronic Kidney Disease Treated receiving Epoetin zeta or other Erythropoietin Stimulating Agents – the BIPS study Yes No
12171 Ongoing Retrospective Cohort Study on the Risk of Venous Thromboembolism with the use of combined oral contraceptives containing Chlormadinone... No No
31817 Finalised Retrospektive Ärztebefragung zu Vorkommen und Ursachen von Stürzen bei älteren Patienten unter besonderer Betrachtung von Antihistaminika der ersten... No No
33796 Ongoing A pregnancy exposure registry study to assess clinical follow-up and outcomes of pregnancies exposed to ulipristal acetate 30 mg. Yes No
35589 Finalised Apothekenbasierte, nicht-interventionelle Unbedenklichkeitsprüfung von Hoggar® Night Tabletten/Schmelztabletten unter Alltagsbedingungen (Projekt... No No
45747 Ongoing Monitoring of the Lenalidomide Pregnancy Prevention Programme (PPP) Implementation and Effectiveness in Germany (Lena-PIE Germany) No No
49520 Ongoing Monitoring of the Lenalidomide Pregnancy Prevention Programme (PPP) Implementation and Effectiveness in Europe (Lena-PIE Europe) No No

PAS by Risk Management Plan (RMP) requirement

Stada Arzneimittel

The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.

Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.